Case Study: a major pharma R&D strategy group improves portfolio investment decisions with Evaluate

Quarterly Key Competitor Event and Catalyst Tracking for a Major Pharma R&D Strategy Group

The R&D Strategy group at a major pharmaceutical company needed to make critical portfolio investment decisions in highly competitive markets where achieving first-to-market status was a major advantage. Their challenge was the fast-moving nature of these drug indications, requiring excellent visibility into competitor activities. To address this, they turned to the vendor Evaluate and its EvaluatePharma data service.

Evaluate's solution combined its proprietary EvaluatePharma data with supplementary research to create a holistic view of the clinical competitive landscape. This was delivered alongside a forward-looking executive summary. The outcome was a significant increase in the client's competitive clarity, which empowered them to strategically direct their resources toward the products with the strongest market positioning and highest commercial potential.